This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Is tumour heterogeneity an issue when assessing PD-L1 status?

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 01:00

Prof. John Gosney explains shares how to overcome the challenges of tumour heterogeneity when testing for PD-L1 in NSCLC. This video was filmed in January 2017.

to keep updated with the latest educational materials in PD-L1 testing

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01090 | Date of Preparation: September 2020

Is tumour heterogeneity an issue when assessing PD-L1 status?

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Length: 01:00

Prof. John Gosney explains shares how to overcome the challenges of tumour heterogeneity when testing for PD-L1 in NSCLC. This video was filmed in January 2017.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-01090 | Date of Preparation: September 2020